Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470958 | 0.98 | LTA4H (0.55) | LTA4HSLC6A9KMT2APOLBMEN1 | |
| SCHEMBL2662926 | 0.92 | LTA4H (0.55) | LTA4HSLC6A9KMT2APOLBMEN1 | |
| SCHEMBL2534850 | 0.86 | CES2 (0.48) | LTA4HCES2CES1GSK3BPTPN1 | |
| Bromide SCHEMBL6284163 | 0.84 | GSK3B (0.60) | CES2CES1GSK3BPTPN1 | |
| Bromide SCHEMBL6282584 | 0.83 | ALDH1A1 (0.41) | KMT2APOLBL3MBTL1CES2CES1 | |
| Bromide SCHEMBL6286087 | 0.83 | CYP19A1 (0.47) | KMT2AMEN1L3MBTL1CES2CES1 | |
| Bromide SCHEMBL6276149 | 0.83 | MEN1 (0.50) | KMT2AMEN1L3MBTL1CES2CES1 | |
| SCHEMBL7149547 | 0.82 | GSK3B (0.62) | CES2CES1GSK3BPTPN1 | |
| Bromide SCHEMBL6284308 | 0.82 | RAB9A (0.41) | KMT2AMEN1L3MBTL1PTGS2KDM4E | |
| Bromide SCHEMBL3888195 | 0.81 | LTA4H (0.37) | LTA4HKMT2ACES2CES1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-07-21 | — | — | US | disclosed |
| WO-2020219591-A1 | THERAPEUTIC METHODS AND COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-10-29 | — | — | WO | disclosed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER CORPSCIENCE AG (DE) | 2010-07-01 | — | — | US | disclosed |
| US-7479501-B2 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050090501-A1 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1140916-B1 | HETEROARYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2002-11-13 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | PIR, PNPO, PDXK | LTA4H 980/4885SLC6A9 4386/4885KMT2A 2548/4885 |
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | LTA4H 825/4885SLC6A9 4736/4885KMT2A 4107/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | LTA4H 1489/4885SLC6A9 4809/4885KMT2A 3564/4885 |
| US-20050090501-A1 | Heteroaryl-cyclic acetals | TNF, TNFRSF1A, CD40 | LTA4H 36/4885SLC6A9 4452/4885KMT2A 3702/4885 |
| US-20220227735-A1 | THERAPEUTIC METHODS AND COMPOUNDS | REN, FURIN, QTRT1 | LTA4H 3380/4885SLC6A9 2142/4885KMT2A 2891/4885 |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | LTA4H 367/4885SLC6A9 1052/4885KMT2A 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.